Abstract
With deep understanding of the biological characteristics of multiple myeloma(MM), treatment diversity, and the improvement of laboratory and imaging technology, the International Myeloma Working Group (IMWG) revised the diagnostic criteria for MM in 2014 and held a conference in Vienna in 2015.In this conference, experts made an interpretation and discussion for the revised diagnostic criteria for MM. Redefined active MM as proportion of clonal bone marrow plasma cells ≥10% or biopsy-proven plasmacytoma and any one or more of the following conditions. Sypercalcaemia, renal insufficiency, anemia and osteolytic bone destruction; super high risk smoldering myeloma biomarkers including proportion of clonal bone marrow plasma cells ≥60%, a serum involved to uninvolved free light chain ratio ≥100, and >1 focal lesions on MRI (each focal lesion must be 5 mm or more in size) were included in the MM diagnostic criteria. Key words: Multiple myeloma; Diagnosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
